SYRE Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 9.70
- P/S (TTM)
- 650.22
- EV/EBITDA
- -7.96
Profitability & growth
- ROE (TTM)
- -23.0%
- Operating margin
- 0.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- 3.11
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Spyre Therapeutics Inc.
Company profileSpyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company is headquartered in Waltham, Massachusetts.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- BUILDING 23, WALTHAM, MA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
